

*Missense mutation of Brain Derived
Neurotrophic Factor (BDNF) alters
neurocognitive performance in patients
with mild traumatic brain injury: a
longitudinal study*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Narayanan, V., Veeramuthu, V., Ahmad-Annuar, A., Ramli, N., Waran, V., Chinna, K., Bondi, M. W., Delano-Wood, L. and Ganesan, D. (2016) Missense mutation of Brain Derived Neurotrophic Factor (BDNF) alters neurocognitive performance in patients with mild traumatic brain injury: a longitudinal study. PLoS ONE, 11 (7). e0158838. ISSN 1932-6203 doi: 10.1371/journal.pone.0158838 Available at <https://centaur.reading.ac.uk/69745/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1371/journal.pone.0158838>

Publisher: Public Library of Science

including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

RESEARCH ARTICLE

Missense Mutation of Brain Derived Neurotrophic Factor (*BDNF*) Alters Neurocognitive Performance in Patients with Mild Traumatic Brain Injury: A Longitudinal Study

Vairavan Narayanan¹*, Vigneswaran Veeramuthu¹*, Azlina Ahmad-Annuar², Norlisah Ramli³, Vicknes Waran¹, Karuthan Chinna⁴, Mark William Bondi^{5,6}, Lisa Delano-Wood^{5,6}, Dharmendra Ganesan¹



OPEN ACCESS

Citation: Narayanan V, Veeramuthu V, Ahmad-Annuar A, Ramli N, Waran V, Chinna K, et al. (2016) Missense Mutation of Brain Derived Neurotrophic Factor (*BDNF*) Alters Neurocognitive Performance in Patients with Mild Traumatic Brain Injury: A Longitudinal Study. PLoS ONE 11(7): e0158838. doi:10.1371/journal.pone.0158838

Editor: Hemachandra Reddy, Texas Tech University Health Science Centers, UNITED STATES

Received: February 19, 2016

Accepted: June 22, 2016

Published: July 20, 2016

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](#) public domain dedication.

Data Availability Statement: Data are from the University of Malaya Mild TBI Study (UM/EC/949.15) whose corresponding authors may be contacted through vicveera@gmail.com / n.vairavan@um.edu.my. The data would be made available to researchers who meet the criteria for access of the confidential data as these data contains the genetic profiles of individual patients with mild head injury.

Funding: This study was partially funded by University Malaya Research Grant (UMRG; RG447-12HTM) (to VN)—Link: <http://umresearch.um.edu.my/>

1 Division of Neurosurgery, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia, **2** Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Wilayah Persekutuan, Malaysia, **3** University Malaya Research Imaging Centre, University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia, **4** Julius Centre University Malaya, Department of Social and Preventive Medicine, University of Malaya, Kuala Lumpur, Malaysia, **5** VA San Diego Healthcare System, San Diego, California, United States of America, **6** University of California San Diego, Department of Psychiatry, San Diego, California, United States of America

☞ These authors contributed equally to this work.

* nvairavan@um.edu.my (VN); vicveera@gmail.com (VV)

Abstract

The predictability of neurocognitive outcomes in patients with traumatic brain injury is not straightforward. The extent and nature of recovery in patients with mild traumatic brain injury (mTBI) are usually heterogeneous and not substantially explained by the commonly known demographic and injury-related prognostic factors despite having sustained similar injuries or injury severity. Hence, this study evaluated the effects and association of the Brain Derived Neurotrophic Factor (*BDNF*) missense mutations in relation to neurocognitive performance among patients with mTBI. 48 patients with mTBI were prospectively recruited and MRI scans of the brain were performed within an average 10.1 (SD 4.2) hours post trauma with assessment of their neuropsychological performance post full Glasgow Coma Scale (GCS) recovery. Neurocognitive assessments were repeated again at 6 months follow-up. The paired t-test, Cohen's d effect size and repeated measure ANOVA were performed to delineate statistically significant differences between the groups [wildtype G allele (Val homozygotes) vs. minor A allele (Met carriers)] and their neuropsychological performance across the time point (T_1 = baseline/ admission vs. T_2 = 6th month follow-up). Minor A allele carriers in this study generally performed more poorly on neuropsychological testing in comparison wildtype G allele group at both time points. Significant mean differences were observed among the wildtype group in the domains of memory ($M = -11.44$, $SD = 10.0$, $p = .01$, $d = 1.22$), executive function ($M = -11.56$, $SD = 11.7$, $p = .02$, $d = 1.05$) and overall performance ($M = -6.89$ $SD = 5.3$, $p = .00$, $d = 1.39$), while the minor A allele carriers

; High Impact Research Grant of University of Malaya (HIR-UM.C/625/1/HIRMOHE/12) (VW)—Link: <http://hir.um.edu.my/>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

showed significant mean differences in the domains of attention ($M = -11.0$, $SD = 13.1$, $p = .00$, $d = .86$) and overall cognitive performance ($M = -5.25$, $SD = 8.1$, $p = .01$, $d = .66$). The minor A allele carriers in comparison to the wildtype G allele group, showed considerably lower scores at admission and remained impaired in most domains across the timepoints, although delayed signs of recovery were noted to be significant in the domains attention and overall cognition. In conclusion, the current study has demonstrated the role of the *BDNF* rs6265 Val66Met polymorphism in influencing specific neurocognitive outcomes in patients with mTBI. Findings were more detrimentally profound among Met allele carriers.

Introduction

Mild traumatic brain injury (mTBI) due to road traffic accident (RTA) is one of the most common forms of head injury, afflicting millions of people worldwide [1–3]. The complex pathophysiology of mTBI and the biochemical responses that occurs thereafter frequently results in cognitive, affective or behavioral deficits [4–6]. A wide variety of complaints and symptoms have been reported [7–11]. The predictability of these deficits are however not straightforward [12]. Crawford et al (2002) and Pruthi et al (2010) in their respective studies noted that the extent and nature of recovery in patients with mTBI are usually heterogeneous and not substantially explained by the commonly known demographic and injury-related prognostic factors [5, 13], despite having sustained similar injuries or injury severity [12, 14–15].

While there are many factors that may contribute to the outcome variability observed in mTBI, reliable genetic or imaging prognostic markers are sparse. In recent years, the expression and modulation of neurotropic genes, both normal and mutated, have been postulated as potential prognostic markers [16]. A wide range of aberrant genes including apolipoprotein E, dopamine β hydroxylase (DBH), catechol-O-methyltransferase (COMT), calcium channel subunit gene (CACNA1A), interleukins α and β , dopamine D2 receptor (DA D2) and brain derived neurotrophic factor (BDNF) has been implicated to modulate the extent of injury [12, 17–19], regulating the cascading neurochemical response to the sudden impact or trauma [12, 17, 20–27], altering the natural recovery pathways [12–13, 28–38], adversely affecting the cognitive recovery processes [32, 39–46] and behavioral functions [17, 46–52]. BDNF has been implicated in many of these repair processes. It is an abundantly available neurotrophin in the brain that is activity dependent [53–55] with a widespread distribution in the cerebral cortex, hippocampus, basal forebrain, striatum and septum areas [56].

BDNF is also known to play a key role in the survival, differentiation, synaptic plasticity and outgrowth of peripheral and central neurons throughout adulthood [57–60]. Missense mutations within this gene are also known to influence both axonal and dendritic morphology where the ocular dominance column development [61–62] and initial dendritic outgrowth are altered [63–64]. While there are over 1768 missense mutations reported in *BDNF* [65], only two are known to influence the expression level of BDNF, rs6265 (c.196G>A, p.V66M, NM_001143814.1) [58, 66] and a dinucleotide GT microsatellite repeat designated as BDNF-linked complex polymorphic region (BDNF-LCPR) located at the 5' UTR [58]. The rs6265 variant has been reported to affect the regulated secretion, neural activation, and neuroplastic effect of BDNF as well as neurocognitive functions in humans [29, 66–67]. It has been associated with memory and learning [29, 68–74] and as well as with aspects of executive functioning [66, 75–80], including response inhibition [75], decision making [77–78], task-switching [79], attention shifting and sequencing [80]. Meanwhile, the BDNF-LCPR variants on the other

hand have been associated with an increased risk for bipolar disorder [81]. The focus of our study, however, was limited to the broad concepts of BDNF-specific phenotype-modulated structural alteration influencing neuro-regeneration (repair and adaptive synaptic organization) [12, 51] and neurogenesis (active production of neurons, astrocytes, glia and other neural lineages) [12, 52] and its relationship with neurocognition.

Six missense mutations in *BDNF* [82–84], namely the rs6265, rs1048218, rs1048220, rs1048221, rs8192466 and rs139352447 were selected. The rs6265 variant has been well studied for its involvement in modulating recovery from brain injury but has yet to be investigated in the Malaysian population. The rs1048220 and rs1048221 are within the crucial protease cleavage site for proBDNF and are reported to impair proBDNF cleavage; and rs1048220 and rs104218 have been associated with Alzheimer's disease [85–89]. However, none of these missense mutations have been explored in brain injury with the exception of rs6265 (BDNF Val66-Met) [18, 20, 32, 40, 46, 58, 66, 75]. Hence, the objective of our study was to assess the effects and association of variations within *BDNF* in relation to neurocognitive performance among patients with mTBI.

Materials and Methods

A total of 61 patients with mTBI who presented to the Emergency Department of University Malaya Medical Center, Kuala Lumpur between April 1st, 2013 and August 31st, 2014 were recruited prospectively. We defined mTBI as an acute head injury, consisting of non-penetrating head trauma resulting in one or more of the following: confusion/disorientation; loss of consciousness (LOC) less than 30 minutes; posttraumatic amnesia (PTA—less than 24 hours in duration); transient focal neurological signs or seizures; and Glasgow Coma Scale of 13 to 15 upon acute clinical evaluation. These patients were assessed with baseline computed tomography (CT) scans of the brain in the emergency department using a Siemens Somatom Sensation 16 CT scanner (Siemens AG, Berlin, Germany). A neuroradiologist (NR) and a neurosurgeon (VN) who were blinded to the clinical diagnosis independently evaluated the images for each patient. Patients who met the study criteria were admitted to the observation ward for 24 hours. Informed consent was obtained upon explaining the objectives of the study and as well as the research protocols/procedures as per the approved guidelines of our local Ethics Committee for the study (UM/EC/949.15). Thirteen patients were later dropped from this study as some refused screening of their genetic profiles, while others were later lost to follow-up, leaving the final sample of 48 patients with their DNA analyzed for genotyping.

Genotyping

DNA was obtained from leukocytes using the phenol-chloroform extraction method [90]. Details of the six SNPs that were examined in this study are in Fig 1. The SNPs were genotyped using Taqman[®] allelic discrimination assays and genotyping was carried out on a 7500 Fast Real-Time PCR machine (Applied Biosystems) using standard protocols as recommended by the manufacturer. Genotypes were confirmed by polymerase chain reaction (PCR) and Sanger sequencing in a random subset of individuals to determine the error rate for each of the Taqman SNP assays (see Fig 2 for the primer sequences).

Neurocognitive assessment

The screening module of Neuropsychological Assessment Battery (S-NAB Form 1) was used to assess the neurocognitive performance of the patients by a clinical neuropsychologist (VV). The assessments were done once the patient had recovered to a GCS score of 15 and was not under any trauma related physical or emotional distress. The S-NAB comprises a

SNP	Variant Position	Allele Change	Chrom o-some	Chromosome Position	Control/ MAF	Patients/ MAF	HapMap- CHB/HCB	HapMap - CHD	HapMap-JPT	HapMap- CEU	ESP- Cohort
¹ rs6265	Val66Met	G to A allele	11	27679916	G= 0.533 A= 0.467	G= 0.563 A= 0.436	G= 0.585 A= 0.415	G= 0.529 A= 0.471	G= 0.628 A= 0.372	G= 0.805 A= 0.195	
² rs1048218	Gln75His	G to T allele	11	27679887	G= 0.978 T= 0.020	G= 0.979 T= 0.020	G= 1.000 T= 0.000		G= 1.000 T= 0.000	G= 1.000 T= 0.000	
³ rs1048220	Arg125Met	G to T allele	11	27679738	G= 1.000 T= 0.000	G= 1.000 T= 0.000	G= 1.000 T= 0.000		G= 1.000 T= 0.000	G= 1.000 T= 0.000	
⁴ rs1048221	Arg127Leu	G to T allele	11	27679732	G= 1.000 T= 0.000	G= 1.000 T= 0.000	G= 1.000 T= 0.000		G= 1.000 T= 0.000	G= 1.000 T= 0.000	
⁵ rs8192466	Thr21Ile	G to T allele	11	27680107	G= 1.000 T= 0.000	G= 1.000 T= 0.000	G= 1.000 T= 0.000		G= 1.000 T= 0.000	G=0.995 T=0.0045	
⁶ rs139352447	Gln75Glu	G to T allele	11	27679889	G= 1.000 T= 0.000	G= 1.000 T= 0.000					G=0.9998 T= 0.0002

Fig 1. List of BDNF SNPs studied, chromosome position, minor allele frequencies and genotyping quality control values of study healthy subjects, patients with mTBI and comparative haplotype groups. Abbreviation: MAF, Minor Allele Frequency; HapMap, Haplotype Map; CHB/HCB, Han Chinese of Beijing; CHD, Han Chinese of Denver, JPT, Japanese of Tokyo; CEU, Northern and Western European Ancestry, Utah; ESP-Cohort, Exome Sequencing Project Cohort. ¹ Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6265. ² Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048218. ³ Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048220. ⁴ Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048221. ⁵ Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8192466. ⁶ Reference minor allele frequency as reported in http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=139352447.

doi:10.1371/journal.pone.0158838.g001

comprehensive set of neuropsychological tests (refer to Fig 3), with demographically corrected norms for adults between the ages of 18 to 97 years. Five cognitive domains i.e attention, memory, language, visuospatial and executive functions are evaluated through this battery. This battery consists of 12 individual tests across the five domains aforementioned. A total of 16 *T* scores are then derived, 14 of which contribute toward five separate Screening Index (domain-specific) scores and one Total Screening Index score [91–92]. The S-NAB Form 2 was used to

SNP ID	Forward Primer, 5'-3'	Reverse Primer, 5'-3'
rs6265	GCAAACATCCGAGGACAAGG	CATTGGGCCGAACCTTTCTGG
rs1048218	GCTTGACATCATTGGCTGAC	AGAAGAGGAGGCTCCAAAGG
rs1048220	CTCTTCTCTTTCTGCTGGAGG	ATACTGTCACACACGCTCAG
rs1048221	TGCTCAGTAGTCAAGTGCCT	TGCCGTTACCCACTCACTAA
rs8192466	TGCAGAAAGGCCTGGAATTA	ACCTTGTCCTCGGATGTTTG
rs139352447	CGTGTACAAGTCTGCGTCCT	ACTCTGGAGAGCGTGAATGG

Fig 2. The primer sequences of 6 SNPs of BDNF studied.

doi:10.1371/journal.pone.0158838.g002

Neuropsychological Assessment (S-NAB Form 1& 2)	
List of S-NAB Module Tests:	Domains Assessed:
Orientation	Orientation
Digits Forward	Attention
Digits Backward	Attention/Working Memory
Numbering and Letters	Attention
Shape Learning Immediate Recognition	Memory
Story Immediate Recall	Memory
Delayed Shape Learning Delayed Recognition	Memory
Story Learning Delayed Recall	Memory
Auditory Comprehension (3 subtests)	Language
Naming	Language
Mazes	Executive Function
Word Generation	Executive Function/ Verbal Fluency
Design Construction	Visuospatial
Visual Discrimination	Visuospatial
Score Clinical Interpretation	Standard Score Range
Very Superior	130-155
Superior	115-129
Above Average	107-114
Average	92-106
Below Average	85-91
Mildly Impaired	77-84
Mildly to Moderately Impaired	70-76
Moderately-Impaired	62-69
Moderately-to-Severely Impaired	55-61
Severely-Impaired	45-54

Fig 3. List S-NAB module subtests and areas of cognitive domains assessed, standard score range of individual domains in S-NAB, and clinical interpretation of the scores.

doi:10.1371/journal.pone.0158838.g003

repeat the same subtests in the screening module at 6 months by the same neuropsychologist to assess the neurocognitive performance longitudinally.

Statistical analysis

All data management and analyses were performed using the SPSS statistical software (Version 22.0). Independent *t*-test was used to establish the differences in demographic features of the sample, if any, based on their *BDNF* SNPs and allele status. The mean differences of the standard score (SS) across the time points against the allele carrier status [wildtype G allele (Val homozygotes) vs. minor A allele (Met carriers)] were then analyzed using the paired *t*-test for both categories. The Cohen's *d* effect size (ES) was also used to measure the magnitude of the differences and a comparison of the ES was done. Repeated measure ANOVA was then performed to delineate statistically significant differences between the groups and their neuropsychological performance across the time point (T_0 = baseline/ admission vs. T_1 = 6th month follow-up). The Bonferroni post hoc correction for both multiple comparison and confidence interval adjustment were administered. Any statistically significant ($p < 0.05$) major effects and interaction were then noted. To assess the association between the allele carrier status and neurocognitive performance, the Spearman correlation coefficient test was also used.

Results

Demographic Characteristics

The demographic characteristics of the study patients are presented in Fig 4. The study patients were predominantly young males (87.5%), within the age range of 18 to 53 (75.0%) with a mean age of 27.4 (SD 8.9). These patients had an average of 11.4 (SD 2.0) years of formal education. The baseline (T_1) neuropsychological assessment was conducted after the full GCS recovery of the patients with an average turnaround time of 4.8 hours (SD 7.9) post trauma, while the repeat neuropsychological assessment was done at an average of 6.1 (SD 0.1) months. In order to look at clinically meaningful markers influenced by specific genotypes, we stratified the group according to the SNPs (involving only rs6265 and rs1048218 as the rest of the SNPs were monomorphic as discussed below) and their allele status. No statistically significant differences were observed within the groups except in the presence of LOC ($t = -2.026$, $df = 46$, $p = 0.049$), with a higher incidence among the A minor allele carriers.

Genetic results and correlation with neurocognitive performance

Genotype distribution and minor allele frequency. Six *BDNF* mutations were examined, of which four (rs1048220, rs1048221, rs8192466, rs139352447) were found to be monomorphic. Only rs6265 and rs1048218 were found to be polymorphic in our population (refer to Fig 1). Both the controls and patients conformed to the Hardy-Weinberg equilibrium for rs6265 and rs1048218. The minor allele frequency for rs6265 was 46.7% in controls compared to the patients (43.6%), but this was not significantly different ($p = .380$). The high MAF values is comparable to what has been reported previously [93–97] and as annotated for East Asians in the HapMap (41.8%) and 1000genomes (48.8%).

The rs1048218 variant had a low MAF in our population (2% in controls) that is also similar to what has been reported previously and in HapMap and 1000genomes. As the variant was present at a similar frequency in both the patients and controls, no further correlation analysis was performed with this variant.

***BDNF* rs6265 vs. neurocognitive performance.** Individuals with the A minor allele (corresponding to Met carriers—Met homozygotes/ Met heterozygotes) generally performed more poorly on neuropsychological testing in comparison to those with the wildtype G allele (corresponding to the Val homozygotes) at both time points. Fig 5 presents the significant mean differences as observed among the group wildtype G allele in the domains of memory ($M =$

Demography		Mean	SD		
Age		27.4	8.9		
Education (in years)		11.4	1.98		
Gender % of Male		87.5			
Right Handedness (%)		87.5			
Age Category (%)					
Between 18- 30		75.0			
Between 31-50		22.9			
Between 51-60		2.1			
SNP/Allele Carrier Status					
Clinical Measure	Score/ Category	rs6265		rs1048218	
		Wildtype G Allele (n=16)	Minor A Allele(n=32)	Wildtype G Allele (n=45)	Minor T Allele (n=3)
		%	%	%	%
GCS	GCS 15	18.8	39.6	54.2	4.2
	GCS 14	8.3	20.8	29.2	0
	GCS 13	6.3	6.3	10.4	2.1
LOC	Yes	31.3	50	77.1	4.2
	None	2.1	16.7	16.7	2.1
PTA	Yes	27.1	47.9	70.8	4.2
	None	6.3	18.8	22.9	2.1
GOSE	GOSE 8.0	29.2	56.3	81.3	4.2
	GOSE 7.0	4.2	10.4	12.5	2.1

Fig 4. Mean of demographic details and stratified allele status specific clinical measures (in percentage).

doi:10.1371/journal.pone.0158838.g004

-11.44, SD 10.0, $p = .01$, $d = 1.22$), executive function ($M = -11.56$, SD = 11.7, $p = .02$, $d = 1.05$) and overall performance ($M = -6.89$ SD = 5.3, $p = .00$, $d = 1.39$), while the group with the minor A allele showed significant mean differences in the domains of attention ($M = -11.0$, SD = 13.1, $p = .00$, $d = .86$) and overall cognitive performance ($M = -5.25$, SD = 8.1, $p = .01$, $d = .66$).

Further comparison of the effect size by the measurement (i.e. domain-specific SS) demonstrated that the patients with wildtype G allele were 5.86 times more likely to perform better in the domains of attention, 1.8 times in memory, 2.82 times in executive function and 2.1 times higher in overall cognition (total index score) in comparison to the A minor allele over time. Individuals with the minor allele showed considerably lower scores at admission and remained impaired in most domains across the time points, although delayed signs of recovery were noted to be significant in the domains attention and overall cognition.

ANOVA tests revealed that the different time points (T_1 = admission and T_2 = 6 month follow-up) produced a significant main effect on neuropsychological SS [$F(6,22) = 5.786$, $p < 0.001$, $\eta_p^2 = .616$], which was largely influenced by allele status [$F(6,22) = 1.997$, $p = 0.110$,

		Paired Samples Test									
Allele Status	Neuocognitive Function Baseline (T ₀) - Follow Up (T ₁)	Paired Differences					t	df	Sig. (2-tailed)	Cohen'd Effect Size	Comparing ES by the measurement
		Mean	Std. Deviation	Std. Error Mean	99% CI of the Difference						
					Lower	Upper					
Wildtype G Allele (Val/Val)	AttentionT ₀ – AttentionT ₁	-5.89	9.5	3.2	-16.49	4.71	-1.86	8	0.10	0.66	0.76
	LanguageT ₀ - LanguageT ₁	2.89	16	5.3	-15	20.78	0.54	8	0.60	0.19	0.67
	MemoryT ₀ – MemoryT ₁	-11.44	10	3.3	-22.6	-0.29	-3.44	8	0.01	1.22	5.86
	SpatialT ₀ – SpatialT ₁	2.89	11	3.7	-9.39	15.17	0.79	8	0.45	0.28	1.8
	ExecutiveT ₀ - ExecutiveT ₁	-11.56	11.7	3.9	-24.65	1.54	-2.96	8	0.02	1.05	2.82
	OverallT ₀ - OverallT ₁	-6.89	5.3	1.8	-12.77	-1.01	-3.93	8	0.00	1.39	2.1
Minor A Allele (Met carriers)	AttentionT ₀ – AttentionT ₁	-11	13.1	2.9	-19.37	-2.63	-3.76	19	0.00	0.86	1.31
	LanguageT ₀ - LanguageT ₁	-6.95	25.1	5.6	-22.99	9.09	-1.24	19	0.23	0.28	1.48
	MemoryT ₀ – MemoryT ₁	3.2	15.8	3.5	-6.92	13.32	0.91	19	0.38	0.21	0.17
	SpatialT ₀ – SpatialT ₁	-2	13.2	3	-10.46	6.46	-0.68	19	0.51	0.16	0.56
	ExecutiveT ₀ - ExecutiveT ₁	-6	16.6	3.7	-16.59	4.59	-1.62	19	0.12	0.37	0.36
	OverallT ₀ - OverallT ₁	-5.25	8.1	1.8	-10.45	-0.05	-2.89	19	0.01	0.66	0.48

Fig 5. Paired-sample t-test, Cohen's *d* effect size (ES) calculation, and the comparison of ES by the measurement of the domain specific standard scores (SS) across the time points (admission vs. 6 month follow up) based on the *BDNF* rs6265 allele status.

doi:10.1371/journal.pone.0158838.g005

$\eta_p^2 = .353$] based on the η_p^2 value (Eta-squared effect size: 0.02 = small, 0.13 = moderate and 0.3 = large). Some interactions were seen in the neurocognitive domains of attention [$F(1,27) = 1.103, p = 0.303$], language, $F(1,27) = 1.159, p = 0.291$, visuospatial, $F(1,27) = 0.935, p = 0.342$ and executive function [$F(1,27) = 0.820, p = 0.373$] [as seen in estimated marginal means (EMM) plot in Fig 6A, 6B, 6D and 6E]. However, only memory [Fig 6C] had a statistically significant interaction with the allele status [$F(1,27) = 6.476, p = 0.02$]. The overall performance showed no interaction [$F(1,27) = 0.305, p = 0.585$] [see Fig 6F] across the time points and allele status.

No statistically significant associations were observed across the neurocognitive domains and specific allele status with the exception of the memory SS score at 6 months ($r = -0.412, p = 0.05$). The memory scores of patients with the A allele were observed to be significantly lower at six months follow-up.

Discussion

We explored the prevalence and possible association of six *BDNF* mutations with specific neurocognitive functions in patients with mTBI over time. We observed a possible protective effect of the G allele in rs6265, with better performance in the domains of attention, executive function, memory, and overall cognition among patients with mTBI. The "finer" performance by those patients with the wildtype G allele in both neurocognitive and neurobehavioral measures, have been consistently reported by other studies involving other CNS pathologies as well [32, 88, 98–99].

For example, McAllister et al (2012) demonstrated that patients with mTBI reported better performance on measures of processing speed longitudinally among the G allele homozygotes as opposed to those who were homozygote for the A allele [32]. Similarly, Chao, Kao and




Fig 6. Estimated marginal mean of patients with mTBI, stratified according to their genetic allele status and their domain specific neuropsychological test standard scores across timepoints. (A) Non-significant changes in the attention domain standard score (SS) overtime, with Met carrier performing poorly in the acute stage. (B) Non-significant changes in the language domain standard score (SS) overtime, with the Met carriers, performing poorly acutely, and remaining so overtime. (C) Significant interaction between the allele carrier status and change in memory SS over time with the Met allele carriers showing signs of deterioration at 6 months post trauma. (D) Non-significant changes in the visuospatial SS, intact in both allele groups. (E) Non-significant interactions between allele carrier status and neurocognitive performance within the domains of executive function, with the SS recovery rate being slower in the Met allele carriers. (F) Non-significant changes in the overall index SS, with the Met allele carriers remaining impaired over time.

doi:10.1371/journal.pone.0158838.g006

Porton (2008) reported that the age of schizophrenia onset in a group of non-related African American patients ($n = 42$) was significantly later in G allele homozygotes [88]. Moreover, Perkovic et al (2014) showed that patients with schizophrenia who were G allele homozygotes were better responders to pharmacotherapeutic treatment and demonstrated significant improvement of clinical symptoms, including lesser conceptual disorganization and delusions [99].

While some studies have reported increased neurocognitive vulnerability in G allele homozygotes [69, 100–102], we believe that the superior neurocognitive performance we observed in our study may be due to the possibility that the G homozygous allele is associated with increased activity dependent secretion of BDNF, increased synaptic plasticity, and better hippocampus dependent memory and cognitive performance [99]. These mechanistic processes have been well explicated in the works of Egan et al (2003) and Kauppi et al (2013) [29, 72]. The divergent influence of haplotype specific variants cannot be overlooked as well.

On the other hand, patients with the A allele in our study revealed mostly non-significant trends of impaired neurocognitive performance with some interactions seen across the time points in the domains of executive function and overall cognition. Additionally, the memory domain saw statistically significant interaction over time and was also negatively associated

with allele status, with evidence of regressing memory function at 6 months among the patients with the G allele. Kauppi et al (2013) noted that this preferential effect on memory is in line with the role of BDNF in the molecular processes underlying memory acquisition. Mechanistically, hippocampal or para-hippocampal BDNF is secreted during neural activation [72]. The increased postsynaptic level of BDNF is known to influence the formation of new synapses in the late phase long term potentiation (LTP), a process that is crucial for the acquisition and storage of long term memories. A successful completion of this crucial molecular process is however impeded when the activity dependent secretion and intracellular trafficking of BDNF is reduced in the protein [29, 72].

Taken together, findings of the current study are the following: (1) only two non-synonymous alterations of the amino acid were present in our study population (rs6265/Val66Met and rs1048218) and the rest of the remaining variants were monomorphic in nature; (2) mTBI patients with BDNF rs6265 Val homozygous allele showed significant differences in their neurocognitive performance and were more likely to perform better than the Met carriers in the domains of attention, memory, executive function and overall performance, both acutely and over time; (3) the Met allele carriers of BDNF rs6265 had considerably low standard scores in most neurocognitive domains observed longitudinally; (4) there was a significant main effect of the time points, and the influence of specific allele status on neurocognitive performance observed; and (5) longitudinal change in memory performance with evidence of deteriorating performance among the A minor allele group (Met carriers) was observed. Strengths of the study include a relatively well characterized homogeneous group of patients in terms of injury type or severity, a short time frame from the time of injury to neurocognitive testing, detection of early neuropsychological deficits in the acute stage, and a consistent reassessment interval at 6 months post trauma. However, there are certain limitations in our study that are worth noting. First, the method of dichotomizing the patients' allele carrier status category (wildtype G allele vs. A minor allele, both the homozygous and heterozygotes) may have unequally diminished the dual allele effect of the A minor allele homozygous vs. heterozygotes (Met/Met vs. Val/Met) on the neurocognitive performance. Additionally, the sample size representing each arms of the rs6265 polymorphism was rather small and should be increased in future longitudinal studies.

Conclusion

In conclusion, the current study has demonstrated the role of the BDNF rs6265 Val66Met polymorphism in influencing specific neurocognitive outcomes in patients with mTBI. Findings were more detrimentally profound among Met allele carriers. Our results strongly suggest that the role of the Val66Met polymorphism in influencing neurostructural alterations and cognitive and behavioral changes post-mTBI should be further explored. Such investigation in future studies may have significant influence over the ways in which mTBI patients are currently managed and their outcomes predicted.

Author Contributions

Conceived and designed the experiments: VN VV AA. Performed the experiments: VN VV AA. Analyzed the data: VN VV AA KC. Contributed reagents/materials/analysis tools: AA VN NR DG. Wrote the paper: VN VV AA NR MWB LD KC VW DG.

References

1. Coronado VG, Xu L, Basavaraju SV, McGuire LC, Wald MM, Faul MD, et al. Surveillance for traumatic brain injury-related deaths: United States, 1997–2007. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.

2. World Health Organization. Global status report on road safety: time for action. Geneva, Switzerland, WHO: 2009.
3. World Health Organization. WHO global status report on road safety 2013: supporting a decade of action. Geneva, Switzerland, WHO: 2013.
4. World Health Organization. Neurological Disorders: Public Health Challenges, Geneva, Switzerland, WHO: 2006.
5. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S, Waisman M, Michaels L, et al. APOE genotype influences acquisition and recall following traumatic brain injury. *Neurology* 2002; 58(7): 1115–1118. PMID: [11940706](#)
6. Anderson GD, Temkin NR, Dikmen SS, Diaz-Arrastia R, Machamer JE, Farhrenbruch C et al. Haptoglobin phenotype and apolipoprotein E polymorphism: relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury. *Epilepsy & Behavior* 2009; 16(3): 501–506.
7. Kushner D. Mild traumatic brain injury: toward understanding manifestations and treatment. *Arch Internal Med*, 1998; 158(15): 1617–1624.
8. Blyth BJ, Bazarian JJ. Traumatic alterations in consciousness: traumatic brain injury. *Emerg Med Clin North Am*, 2010; 28(3): 571–594. doi: [10.1016/j.emc.2010.03.003](#) PMID: [20709244](#)
9. Willer B, Leddy JJ. Management of concussion and post-concussion syndrome. *Curr Treat Options Neurol* 2006; 8(5): 415–426. PMID: [16901381](#)
10. Marshall S, Bayley M, McCullagh S, Velikonja D, Berrigan L. Clinical practice guidelines for mild traumatic brain injury and persistent symptoms. *Can Fam Physician* 2012; 58(3): 257–267. PMID: [22518895](#)
11. Ashman TA, Gordon WA, Cantor JB, Hibbard MR. Neurobehavioral consequences of traumatic brain injury. *Mt Sinai J Med* 2006; 73(7): 999–1005. PMID: [17195886](#)
12. McAllister TW. Genetic factors modulating outcome after neurotrauma. *PM&R* 2010; 2(12): S241–S252.
13. Pruthi N, Chandramouli BA, Kuttapa TB Rao SL, Subbaskrishna DK, Abraham MP, et al. Apolipoprotein E Polymorphism and Outcome after Mild to Moderate TBI: A Study of Patient Population in India. *Neurol India* 2010; 58 (2): 264–269. doi: [10.4103/0028-3886.63810](#) PMID: [20508347](#)
14. Dikmen S, Machamer J, Fann JR, Tenkin NR. Rates of symptom reporting following traumatic brain injury. *J Intl Neuropsychol Soc* 2010; 16: 401–411.
15. Stulemeijer M, Van der Werf S, Borm GF, Vos PE. Early prediction of favourable recovery 6 months after mild traumatic brain injury. *J Neurol, Neurosurg Psychiatry* 2008; 79(8): 936–942.
16. Bennett ER, Reuter-Rice K, Laskowitz DT. Genetic Influences in Traumatic Brain Injury. In: Laskowitz D, Grant G, Eds. *Translational Research in Traumatic Brain Injury*. Boca Raton (FL): CRC Press/Taylor and Francis Group; 2016. Chapter 9. Available: <http://www.ncbi.nlm.nih.gov/books/NBK326717/>
17. DeKosky ST, Kochanek PM, Clark RSB, Ciallella JR, Dixon CE. Secondary Injury After Head Trauma: Subacute and Long-term Mechanisms. *Semin Clin Neuropsychiatry* 1998; 3(3): 176–185. PMID: [10085205](#)
18. Michael DB, Byers DM, Irwin LN. Gene expression following traumatic brain injury in humans: analysis by microarray. *J Clin Neurosci* 2005; 12(3), 284–290. PMID: [15851083](#)
19. Dutcher SA, Michael DB. Gene expression in neurotrauma. *Neurol Res* 2001; 23(2–3): 203–206. PMID: [11320600](#)
20. Gennarelli TA, Graham DI. Neuropathology. In *Textbook of traumatic brain injury*. Silver JM, McAlister TW, Yudofsky SC, editors. Washington DC, American Psychiatric Publishing; 2005. p. 27–50.
21. Laurer HL, McIntosh TK. Pharmacologic therapy in traumatic brain injury: update on experimental treatment strategies. *Curr Pharm Des* 2001; 7(15): 1505–1516. PMID: [11562295](#)
22. Martinez-Lucas P, Moreno-Cuesta J, Garcia-Olmo DC, Sanchez-Sanchez F, Escribano-Martinez J, del Pozo AC, Lizan-Garcia M, et al. Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury. *Intensive Care Med* 2005; 31: 1168–1173. PMID: [16007417](#)
23. Kors EE, Terwindt GM, Vermeulen FL, Fitzsimons RB, Jardine PE, Heywood P, et al. Delayed cerebral edema and fatal coma after minor head trauma: Role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. *Ann Neurol* 2001; 49: 753–760. PMID: [11409427](#)
24. Stam AH, Luijckx GJ, Ginjaar IB, Frants RR, Haan J, Ferrari MD, et al. Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. *J Neurol Neurosurg Psychiatry* 2009; 80: 1125–1129. doi: [10.1136/jnnp.2009.177279](#) PMID: [19520699](#)

25. Uzan M, Tanriverdi T, Baykara O, Kafadar A, Sanus GZ, Tureci E, et al. Association between interleukin-1beta (IL-1b) gene polymorphism and outcome after head injury: An early report. *Acta Neurochir* 2005; 147: 715–720. PMID: [15891809](#)
26. Winter CD, Pringle AK, Clough GF, Church MK. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. *Brain* 2004; 127: 315–320. PMID: [14645145](#)
27. Quan N, Herkenham M. Connecting cytokines and brain: A review of current issues. *Histol Histopathol* 2002; 17: 273–288. PMID: [11813877](#)
28. Hicks RR, Numan S, Dhillon HS, Prasad MR, Seroogy KB. Alterations in BDNF and NT-3 mRNAs in rat hippocampus after experimental brain trauma. *Mol Brain Res* 1997; 48: 401–406. PMID: [9332737](#)
29. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003; 112(2): 257–69. PMID: [12553913](#)
30. Poo M. Neurotrophins as synaptic modulators. *Nat Rev Neurosci* 2001; 2: 24–32. PMID: [11253356](#)
31. Hicks RR, Zhang L, Dhillon HS, Prasad MR, Seroogy KB. Expression of trkB mRNA is altered in rat hippocampus after experimental brain trauma. *Mol Brain Res* 1998; 59: 264–268. PMID: [9729420](#)
32. McAllister TW, Tyler AL, Flashman LA, Rhodes CH, McDonald BC, Saykin AJ, et al. Polymorphisms in the brain-derived neurotrophic factor gene influence memory and processing speed one month after brain injury. *J Neurotrauma* 2012; 29(6): 1111–1118. doi: [10.1089/neu.2011.1930](#) PMID: [22188054](#)
33. Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. *J Neurosci* 2002; 22: 10083–10087. PMID: [12451108](#)
34. Nathoo N, Chetry R, van Dellen JR, Connolly C, Naidoo R. Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: Influence of ethnic and regional differences. *J Neurosurg* 2003; 98: 302–306. PMID: [12593615](#)
35. Chiang MF, Chang JG, Hu CJ. Association between apolipoprotein E genotype and outcome of traumatic brain injury. *Acta Neurochir* 2003; 145: 649–654. PMID: [14520543](#)
36. Alexander S, Kerr ME, Kim Y, Kamboh MI, Beers SR, Conley YP. Apolipoprotein E4 allele presence and functional outcome after severe traumatic brain injury. *J Neurotrauma* 2007; 24: 790–797. PMID: [17518534](#)
37. Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. *Curr Drug Targets* 2005; 6: 111–126. PMID: [15720218](#)
38. Parasuraman R, Greenwood PM. The apolipoprotein E gene, attention, brain function. *Neuropsychology* 2002; 16: 254–274. PMID: [11949718](#)
39. Morley KI, Montgomery GW. The genetics of cognitive processes: Candidate genes in humans and animals. *Behav Genet* 2001; 31: 511–531. PMID: [11838530](#)
40. Failla MD, Juengst SB, Arenth PM, Wagner AK. Preliminary Associations Between Brain-Derived Neurotrophic Factor, Memory Impairment, Functional Cognition, and Depressive Symptoms Following Severe TBI. *Neurorehabil Neural Repair* 2015; 1545968315600525. PMID: [26276123](#)
41. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: Dopamine, COMT and BDNF. *Genes Brain Behav* 2006; 5: 311–328. PMID: [16716201](#)
42. Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). *Brain Injury* 2005; 19(7): 471–479. PMID: [16134735](#)
43. Bales J. W., Kline A. E., Wagner A. K., & Dixon C. E. (2010). Targeting dopamine in acute traumatic brain injury. *The open drug discovery journal*, 2, 119. PMID: [22308176](#)
44. Yue JK, Winkler EA, McAllister TW, Temkin N, Ferguson A, Lingsma HF, et al. 178 COMT Val158Met is Associated With Domain-Specific Cognitive Impairment Following Mild Traumatic Brain Injury. *Neurosurgery* 2015; 62: 225–225.
45. Kurowski BG, Backeljauw B, Zang H, Zhang N, Martin LJ, Pilipenko V, et al. Influence of Catechol-O-methyltransferase on Executive Functioning Longitudinally After Early Childhood Traumatic Brain Injury: Preliminary Findings. *J Head Trauma Rehabil* 2015; doi: [10.1097/HTR.0000000000000162](#)
46. Failla MD, Conley YP, Wagner AK. Brain-Derived Neurotrophic Factor (BDNF) in Traumatic Brain Injury—Related Mortality Interrelationships Between Genetics and Acute Systemic and Central Nervous System BDNF Profiles. *Neurorehabil Neural Repair* 2016; 30(1): 83–93. doi: [10.1177/1545968315586465](#) PMID: [25979196](#)

47. Ebstein RP, Benjamin J, Belmaker RH. Personality and polymorphisms of genes involved in aminergic neurotransmission. *Eur J Pharmacol* 2000; 410:205–214. PMID: [11134670](#)
48. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, et al. A study of the dopamine D2 receptor gene in pathological gambling. *Pharmacogenet Genomics* 1996; 6(3): 223–234.
49. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O methyltransferase deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. *Proc Natl Acad Sci* 1998; 95: 9991–9996. PMID: [9707588](#)
50. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, et al. Evidence of common and specific genetic effects: Association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. *Hum Mol Genet* 2004; 13: 1903–1911. PMID: [15229186](#)
51. Ariza M, Pueyo R, Matarin Mdel M, Junque C, Mataro M, Clemente I, et al. Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury. *J Neurol, Neurosurg Psychiatry* 2006; 77(10): 1191–1193.
52. McAllister TW. Genetic factors in traumatic brain injury. *Handb Clin Neurol* 2014; 128: 723–739.
53. Karpova NN. Role of BDNF epigenetics in activity-dependent neuronal plasticity. *Neuropharmacology* 2014; 76: 709–718 doi: [10.1016/j.neuropharm.2013.04.002](#) PMID: [23587647](#)
54. Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. *Dev Neurobiol*, 2010; 70(5): 271–288. doi: [10.1002/dneu.20774](#) PMID: [20186709](#)
55. Korley FK, Diaz-Arrastia R, Wu AH, Yue JK, Manley GT, Sair HI, et al. Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury. *J Neurotrauma* 2016; 33(2): 215–225. doi: [10.1089/neu.2015.3949](#) PMID: [26159676](#)
56. Wang H, Zhang Y, Qiao M. Mechanisms of extracellular signal-regulated kinase/cAMP response element-binding protein/brain-derived neurotrophic factor signal transduction pathway in depressive disorder. *Neural Regen Res* 2013; 8(9): 843. doi: [10.3969/j.issn.1673-5374.2013.09.009](#) PMID: [25206732](#)
57. Huang CC, Liu ME, Chou KH, Yang AC, Hung CC, Hong CJ, et al. Effect of BDNF Val66Met polymorphism on regional white matter hyperintensities and cognitive function in elderly males without dementia. *Psychoneuroendocrinology* 2014; 39: 94–103. doi: [10.1016/j.psyneuen.2013.09.027](#) PMID: [24275008](#)
58. Rostami E, Krueger F, Zoubak S, Dal-Monte O, Raymont V, Pardini M, et al. BDNF polymorphism predicts general intelligence after penetrating traumatic brain injury. *PloS One* 2011; 6(11): e27389. doi: [10.1371/journal.pone.0027389](#) PMID: [22087305](#)
59. Binder DK, Scharfman HE. Mini review. *Growth Factors* 2004; 22(3): 123–131. PMID: [15518235](#)
60. Hong CJ, Liou YJ, Tsai SJ. Effects of BDNF polymorphisms on brain function and behavior in health and disease. *Brain Res Bul* 2011; 86(5): 287–297.
61. Cabelli RJ, Shelton DL, Segal RA, Shatz CJ. Blockade of endogenous ligands of trkB inhibits formation of ocular dominance columns. *Neuron*, 1997; 19(1): 63–76. PMID: [9247264](#)
62. Horch HW, Kruttgen A, Portbury SD, Katz, LC. Destabilization of cortical dendrites and spines by BDNF. *Neuron* 1999; 23(2): 353–364. PMID: [10399940](#)
63. McAllister AK, Katz LC, Lo DC. Neurotrophin regulation of cortical dendritic growth requires activity. *Neuron* 1996; 17(6): 1057–1064. PMID: [8982155](#)
64. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. *Ann Rev Neuroscience* 1999; 22(1): 295–318.
65. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; 491(7422): 56–65. doi: [10.1038/nature11632](#) PMID: [23128226](#)
66. Barbey AK, Colom R, Paul E, Forbes C, Krueger F, Goldman D, et al. Preservation of general intelligence following traumatic brain injury: contributions of the Met66 brain-derived neurotrophic factor. *PloS One* 2014; 9(2): e88733. doi: [10.1371/journal.pone.0088733](#) PMID: [24586380](#)
67. Tost H, Alam T, Geramita M, Rebsch C, Kolachana B, Dickinson D, et al. Effects of the BDNF Val66-Met polymorphism on white matter microstructure in healthy adults. *Neuropsychopharmacology* 2013; 38(3): 525–532. doi: [10.1038/npp.2012.214](#) PMID: [23132269](#)
68. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. *J Neurosci* 2003; 23(17): 6690–6694. PMID: [12890761](#)
69. Bekinschtein P, Cammarota M, Izquierdo I, Medina JH. Reviews: BDNF and memory formation and storage. *Neuroscientist* 2008; 14(2): 147–156. PMID: [17911219](#)

70. Miyajima F, Ollier W, Mayes A, Jackson A, Thacker N, Rabbitt, et al. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. *Genes, Brain and Behav* 2008; 7 (4): 411–417.
71. Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D et al. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. *Arch Gen Psychiatry*, 2011; 68(2): 198–206. doi: [10.1001/archgenpsychiatry.2010.194](https://doi.org/10.1001/archgenpsychiatry.2010.194) PMID: [21300947](https://pubmed.ncbi.nlm.nih.gov/21300947/)
72. Kauppi K, Nilsson LG, Adolfsson R, Lundquist A, Eriksson E, Nyberg L. Decreased medial temporal lobe activation in BDNF 66 Met allele carriers during memory encoding. *Neuropsychologia* 2013; 51 (12): 2462–2468. doi: [10.1016/j.neuropsychologia.2012.11.028](https://doi.org/10.1016/j.neuropsychologia.2012.11.028) PMID: [23211991](https://pubmed.ncbi.nlm.nih.gov/23211991/)
73. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, et al. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. *Neurosci Res* 2008; 61(4): 360–367. doi: [10.1016/j.neures.2008.04.003](https://doi.org/10.1016/j.neures.2008.04.003) PMID: [18501457](https://pubmed.ncbi.nlm.nih.gov/18501457/)
74. Ninan I. Synaptic regulation of affective behaviors; role of BDNF. *Neuropharmacology* 2014; 76: 684–695. doi: [10.1016/j.neuropharm.2013.04.011](https://doi.org/10.1016/j.neuropharm.2013.04.011) PMID: [23747574](https://pubmed.ncbi.nlm.nih.gov/23747574/)
75. Krueger F, Pardini M, Huey ED, Raymont V, Solomon J, Lipsky RH, et al. The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combat-related traumatic brain injury. *J Neurosci*, 2011; 31(2): 598–606. doi: [10.1523/JNEUROSCI.1399-10.2011](https://doi.org/10.1523/JNEUROSCI.1399-10.2011) PMID: [21228168](https://pubmed.ncbi.nlm.nih.gov/21228168/)
76. Beste C, Kolev V, Yordanova J, Domschke K, Falkenstein M, Baune BT, et al. The role of the BDNF Val66Met polymorphism for the synchronization of error-specific neural networks. *J Neurosci* 2010; 30(32): 10727–10733. doi: [10.1523/JNEUROSCI.2493-10.2010](https://doi.org/10.1523/JNEUROSCI.2493-10.2010) PMID: [20702703](https://pubmed.ncbi.nlm.nih.gov/20702703/)
77. Rybakowski JK, Borkowska A, Czerski PM, Skibinska M, Hauser J. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. *Bipolar Disord*, 2003; 5(6): 468–472. PMID: [14636373](https://pubmed.ncbi.nlm.nih.gov/14636373/)
78. Rybakowski JK, Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. *Mol Psychiatry*, 2006; 11(2): 122–124. PMID: [16222333](https://pubmed.ncbi.nlm.nih.gov/16222333/)
79. Gajewski PD, Hengstler JG, Golka K, Falkenstein M, Beste C. The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. *Neurobiol Aging*, 2011; 32(12): 2327.e7–2327.e19.
80. Getzmann S, Gajewski PD, Hengstler JG, Falkenstein M, Beste C. BDNF Val66Met polymorphism and goal-directed behavior in healthy elderly—evidence from auditory distraction. *NeuroImage* 2013; 64: 290–298. doi: [10.1016/j.neuroimage.2012.08.079](https://doi.org/10.1016/j.neuroimage.2012.08.079) PMID: [22963854](https://pubmed.ncbi.nlm.nih.gov/22963854/)
81. Okada T, Hashimoto R, Numakawa T, Iijima Y, Kosuga A, Tatsumi M, et al. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. *Mol Psychiatry* 2006; 11(7): 695–703. PMID: [16568151](https://pubmed.ncbi.nlm.nih.gov/16568151/)
82. UniProt Consortium. UniProtKB—P23560 (BDNF_HUMAN) [online] Available: http://www.uniprot.org/uniprot/P23560#subcellular_location [Accessed 23 October, 2015]
83. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl. *Nucleic Acids Res* 2015; 43: D662–D669. doi: [10.1093/nar/gku101](https://doi.org/10.1093/nar/gku101)
84. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001; 29(1): 308–11. PMID: [11125122](https://pubmed.ncbi.nlm.nih.gov/11125122/)
85. Lin WJ, Salton SR. The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms. *Front Endocrinol*, 2013; 4.
86. Huang R, Huang J, Cathcart H, Smith S, Poduslo SE. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. *J Med Genets* 2007; 44(2): e66.
87. Jonsson EG, Edman-Ahlbom B, Sillen A, Gunnar A, Kulle B, Frigessi A, et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30(5): 924–933. PMID: [16581172](https://pubmed.ncbi.nlm.nih.gov/16581172/)
88. Chao HM, Kao HT, Porton B. BDNF Val66Met variant and age of onset in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 2008; 147(4): 505–506.
89. Weese-Mayer DE, Bolk S, Silvestri JM, Chakravarti A. Idiopathic congenital central hypoventilation syndrome: Evaluation of brain-derived neurotrophic factor genomic DNA sequence variation. *Am J Med Genet A*, (2002; 107(4): 306–310.
90. Miller SA, Dykes DD, Polesky HFRN. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 16(3): 1215. PMID: [3344216](https://pubmed.ncbi.nlm.nih.gov/3344216/)
91. Veeramuthu V, Narayanan NV, Tan LK, Delano-Wood L, Chinna K, Bondi MW, et al. Diffusion Tensor Imaging Parameters in Mild Traumatic Brain Injury and Its Correlation with Early Neuropsychological

- Impairment: A Longitudinal Study. *J Neurotrauma* 2015; 32(19): 1497–1509. doi: [10.1089/neu.2014.3750](https://doi.org/10.1089/neu.2014.3750) PMID: [25952562](https://pubmed.ncbi.nlm.nih.gov/25952562/)
92. Stern RA, White T. Neuropsychological Assessment Battery. Lutz, FL: Psychological Assessment Resources. 2003.
93. Mohajeri MH, Giese KP. Two selected models of missense mutations in mice for the study of learning behaviour. *Brain Res Bul* 2012; 88(5): 429–433.
94. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. *J Neurosci* 2004; 24(45): 10099–10102. PMID: [15537879](https://pubmed.ncbi.nlm.nih.gov/15537879/)
95. Pivac N, Kim B, Nedic G, Ho-Joo Y, Kozaric-Kovacic D, Pyo Hong J, et al. Ethnic differences in brain derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. *Croat Med J* 2009; 50(1): 49–54.
96. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. *Am J Med Genet B Neuropsychiatr Genet* 2004; 126(1): 122–123.
97. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. *Mol Psychiatry* 2010; 15(8): 810–815. doi: [10.1038/mp.2009.24](https://doi.org/10.1038/mp.2009.24) PMID: [19255578](https://pubmed.ncbi.nlm.nih.gov/19255578/)
98. Kang JI, Namkoong K, Ha RY, Jhung K, Kim YT, Kim S. J. Influence of BDNF and COMT polymorphisms on emotional decision making. *Neuropharmacology* 2010; 58(7): 1109–1113. doi: [10.1016/j.neuropharm.2010.02.001](https://doi.org/10.1016/j.neuropharm.2010.02.001) PMID: [20153759](https://pubmed.ncbi.nlm.nih.gov/20153759/)
99. Perkovic MN, Erjavec GN, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. *Psychopharmacology* 2014; 231(18): 3757–3764. doi: [10.1007/s00213-014-3515-4](https://doi.org/10.1007/s00213-014-3515-4) PMID: [24595507](https://pubmed.ncbi.nlm.nih.gov/24595507/)
100. Dennis NA, Cabeza R, Need AC, Waters-Metenier S, Goldstein DB, LaBar KS. Brain-derived neurotrophic factor val66met polymorphism and hippocampal activation during episodic encoding and retrieval tasks. *Hippocampus* 2011; 21(9): 980–989. doi: [10.1002/hipo.20809](https://doi.org/10.1002/hipo.20809) PMID: [20865733](https://pubmed.ncbi.nlm.nih.gov/20865733/)
101. van Wingen G, Rijpkema M, Franke B, van Eijndhoven P, Tendolkar I, Verkes RJ, et al. The brain-derived neurotrophic factor Val66Met polymorphism affects memory formation and retrieval of biologically salient stimuli. *Neuroimage*, 2010; 50(3), 1212–1218. doi: [10.1016/j.neuroimage.2010.01.058](https://doi.org/10.1016/j.neuroimage.2010.01.058) PMID: [20097294](https://pubmed.ncbi.nlm.nih.gov/20097294/)
102. Harris SE, Fox H, Wright AF, Hayward C, Starr JM, Whalley LJ, et al. The brain-derived neurotrophic factor Val66Met polymorphism is associated with age-related change in reasoning skills. *Mol Psychiatry* 2006; 11(5): 505–513. PMID: [16446742](https://pubmed.ncbi.nlm.nih.gov/16446742/)